Novel hypoglycaemic agents: considerations in patients with chronic kidney disease

Fran Game1

  • 1Department of Diabetes and Endocrinology, Derby Hospitals NHS FT, Derby, UK.

Insights

Managing type 2 diabetes with kidney disease requires careful glucose control. Newer guidelines and agents help balance blood sugar targets with potential drug side effects in patients with renal impairment.

Area of Science:

  • Nephrology
  • Endocrinology
  • Pharmacology

Background:

  • Diabetic kidney disease is a common complication of type 2 diabetes.
  • Tight glycemic control is recommended to prevent diabetes complications.
  • Renal impairment necessitates careful consideration of drug efficacy and safety due to potential metabolite accumulation.

Purpose of the Study:

  • To review glucose-lowering drugs for type 2 diabetes management.
  • To emphasize updated guidelines and newer agents.
  • To address the challenges of glycemic control in patients with renal impairment.

Main Methods:

  • Literature review of current treatment guidelines.
  • Analysis of pharmacokinetic and pharmacodynamic properties of glucose-lowering agents.
  • Evaluation of safety profiles in patients with varying degrees of renal function.

Main Results:

  • Specific glucose-lowering drugs require dose adjustment or avoidance in renal impairment.
  • Newer agents may offer improved safety profiles or alternative mechanisms of action.
  • Balancing glycemic targets with renal function is crucial for optimal patient outcomes.

Conclusions:

  • Treatment decisions for type 2 diabetes with renal disease must be individualized.
  • Clinicians should be aware of drug accumulation risks and adjust therapy accordingly.
  • Ongoing research into safer and more effective glucose-lowering strategies for renally impaired patients is essential.

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
679
Diabetic Nephropathy01:28

Diabetic Nephropathy

Definition Diabetic nephropathy is a chronic kidney complication that results from prolonged hyperglycemia.Prevalence It is the most common cause of chronic kidney disease (CKD) and end-stage renal disease (ESRD) worldwide, affecting up to half of individuals with diabetes.Pathophysiology • Sustained hyperglycemia triggers multiple hemodynamic and metabolic changes in the kidney. • Early in the disease, increased renal blood flow and glomerular hyperfiltration...
32
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
1.4K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
1.1K
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
682